The acquisition is immediately accretive and extends Collegium's revenue runway with long patent protection. Watch for integration execution and prescription trends for AZSTARYS in upcoming quarters. The $300 million term loan increases leverage, but guided EBITDA of $475-$500 million provides strong coverage. Leadership departures are notable but appear orderly.
Price Chart
Executive Summary
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for $650 million in cash, funded by existing cash and a new term loan. The company raised its 2026 guidance to reflect the deal, now expecting product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million. The acquisition is expected to be immediately accretive and extends Collegium's revenue outlook with patent protection through 2037.
Key Financial Metrics
Key Facts
- Acquired AZSTARYS for $650 million in cash, funded by $350 million cash on hand and $300 million from a delayed draw term loan.
- Up to $135 million in additional milestone payments possible.
- AZSTARYS generated over 760,000 prescriptions in 2025; expected to contribute $60-$70 million in net revenue in H2 2026.
- 2026 guidance raised: product revenues $865-$895 million (from $805-$825 million); adjusted EBITDA $475-$500 million (from $455-$475 million).
- Annual run-rate synergies expected to exceed $50 million within 12 months.
- AZSTARYS has six Orange Book-listed patents, most expiring December 2037.
- Two leadership departures: CCO Scott Dreyer (end of August 2026) and CMO Thomas Smith (transition period).
Financial Impact
$650 million upfront cash acquisition, plus up to $135 million in milestones; 2026 revenue guidance raised by $60-$70 million; EBITDA guidance raised by $20-$25 million.
Risk Factors
- Integration risk: realizing $50 million+ synergies within 12 months may be challenging.
- Increased leverage from $300 million term loan; debt service costs could pressure margins.
- AZSTARYS revenue guidance of $60-$70 million for H2 2026 may be optimistic if prescription growth slows.
- Leadership departures of CCO and CMO could disrupt commercial and medical strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Court Ruling | $28.74 $22.38 | ▼ −22.13% | ▼ −20.18% | $22.08 (−23.19%) |
Aug 13, 2026 7w ago | 8-K | $28.15 $22.75 | ▼ −19.18% | ▼ −17.44% | $22.08 (−21.58%) |
Aug 6, 2026 8w ago | 8-K | $29.11 $23.70 | ▼ −18.58% | ▼ −19.18% | $22.08 (−24.17%) |
May 15, 2026 19w ago | Insider Cluster | $33.65 $34.65 | ▲ +2.97% | ▲ +1.39% | $22.08 (−34.40%) |
May 12, 2026 20w ago | Press Release | $35.69 $34.80 | ▼ −2.49% | ▼ −0.77% | $22.08 (−38.15%) |
May 11, 2026 20w ago | 144 | $35.81 $34.40 | ▼ −3.94% | ▼ −3.63% | $22.08 (−38.36%) |
Apr 23, 2026 23w ago | Press Release | $32.28 $34.22 | ▲ +6.01% | ▲ +1.38% | $22.08 (−31.61%) |
Apr 7, 2026 25w ago | 8-K | $33.43 $35.32 | ▲ +5.65% | ▼ −2.89% | $22.08 (−33.97%) |
Mar 19, 2026 28w ago | Press Release | $36.30 $34.41 | ▼ −5.21% | ▼ −12.83% | $22.08 (−39.19%) |
Mar 3, 2026 30w ago | Press Release | $39.99 $33.07 | ▼ −17.30% | ▼ −12.90% | $22.08 (−44.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access